Sage Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$84K Hold
17,977
– – 0.03% 161
2026
Q2
$86.5K Hold
17,977
– – 0.03% 162
2026
Q1
$61.1K Buy
17,977
+1,227
+7% +$4.16K 0.03% 163
2025
Q4
$47.7K Hold
16,750
– – 0.02% 161
2025
Q3
$44.2K Hold
16,750
– – 0.02% 157
2025
Q2
$37.7K Hold
16,750
– – 0.02% 157
2025
Q1
$35.8K Hold
16,750
– – 0.02% 151
2024
Q4
$40.5K Hold
16,750
– – 0.02% 154
2024
Q3
$40.9K Hold
16,750
– – 0.02% 159
2024
Q2
$43K Hold
16,750
– – 0.02% 152
2024
Q1
$48.9K Buy
+16,750
New +$46.8K 0.03% 149

Other funds holding ORMP

Sage Capital Management's ORMP Position: Q3 2026 in Review

Sage Capital Management held its Oramed Pharmaceuticals (ORMP) position steady in Q3 2026 at 17,977 shares worth $84K. The position accounts for 0.03% of the portfolio, ranked #161.

Sage Capital Management first reported a position in ORMP in Q1 2024 and has held it in 11 quarters since. The position peaked at $86.5K in Q2 2026. 8 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.

  • Sage Capital Management held 17,977 shares of Oramed Pharmaceuticals worth $84K as of Q3 2026.
  • Sage Capital Management left its Oramed Pharmaceuticals share count unchanged in Q3 2026.
  • Oramed Pharmaceuticals made up 0.03% of Sage Capital Management's portfolio in Q3 2026, its #161 holding.
  • Sage Capital Management first reported a position in Oramed Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
  • Sage Capital Management's Oramed Pharmaceuticals position peaked at $86.5K in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.

Based on Sage Capital Management's 13F filing for Q3 2026, filed 20 Oct 2026.